Phase II Study Compares Afinitor as Second-Line Treatment Following Various VEGFR Inhibitors and Cytokine Therapy in Renal Cell Carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Progression-free survival data from a phase II study evaluating Afinitor (everolimus) as a second-line therapy in advanced renal cell carcinoma were presented at the annual meeting of the American Society of Clinical Oncology in Chicago.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.

Login